Clinical trialObsCompleted
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
MPACT Extension Study: Multicenter, Survival Data Collection in Subjects Previously Enrolled in Protocol CA046
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- 2 January 2014
- Expected end
- 16 April 2015
- Enrollment
- 40 participants
- Sites
- 39
- Primary outcomes
- Overall Survival
- Sponsor
- Industry
- Results posted
- No
- Last update
- 1 November 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 15
- Backgroundnab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of… DOI 10.2147/ott.s124097↗
- BackgroundTumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory… DOI 10.1097/mpa.0000000000000742↗
- BackgroundEfficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to… DOI 10.1186/s12885-016-2798-8↗
- BackgroundSecond-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic … DOI 10.1038/bjc.2016.185↗
- BackgroundDose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreat… DOI 10.21037/jgo.2016.01.03↗
- Backgroundnab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subg… DOI 10.1007/s12325-016-0327-4↗
- BackgroundCA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-pac… DOI 10.1093/annonc/mdw006↗
- BackgroundPositron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcit… DOI 10.1093/annonc/mdw020↗
- BackgroundDevelopment of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcit… DOI 10.1016/j.ejca.2015.10.017↗
- BackgroundNab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective … DOI 10.1038/bjc.2015.328↗
- Backgroundnab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. DOI 10.1093/jnci/dju413↗
- BackgroundPrognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus… DOI 10.1634/theoncologist.2014-0394↗
- BackgroundFirst-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. PMID 25398812↗
- BackgroundNab-paclitaxel: potential for the treatment of advanced pancreatic cancer. DOI 10.2147/ott.s40705↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗